Genmab: Recruitment Completed in Arzerra (Ofatumumab) Phase II Study in Relapsed DLBCL

27-Jul-2009 - Denmark

Genmab A/S announced it has completed recruitment of 75 patients in the Phase II study of Arzerra(TM) (ofatumumab) to evaluate treatment of relapsed diffuse large B-cell lymphoma (DLBCL) in patients ineligible for or relapsed following a stem cell transplant.

In this open label trial, each patient will receive 8 weekly infusions of ofatumumab. The first infusion will be 300 mg and the 7 subsequent infusions will be 1000 mg of ofatumumab. Disease status will be assessed 4 weeks after the last infusion and then every 3 months for a total of up to 24 months after treatment start. After 24 months, patients will be followed until initiation of alternative DLBCL treatment or month 60.

The objective of the study is to determine the efficacy of ofatumumab in patients with relapsed DLBCL ineligible for transplant or relapsed after transplant. The primary endpoint of the study is objective response over a 6 month period from start of treatment.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

CyBio and Macherey-Nagel collaborate to develop applications for automated DNA/RNA preparation

Innovations for Health: When Molecular Spectroscopy Meets Lasers and Photonics - "An all-optical, minimally invasive and label-free diagnostic tool could represent a significant advance in health..."

Innovations for Health: When Molecular Spectroscopy Meets Lasers and Photonics - "An all-optical, minimally invasive and label-free diagnostic tool could represent a significant advance in health..."

HI viruses crack the lock to the cell nucleus - For the first time, researchers have observed how HIV penetrates the nuclear pores to the genome of human immune cells

HI viruses crack the lock to the cell nucleus - For the first time, researchers have observed how HIV penetrates the nuclear pores to the genome of human immune cells

Closure of Astellas CNS research in Edinburgh

Antibody discovered that blocks almost all known HIV variants in neutralization assays - The discovery potentially opens up new perspectives for the prevention and treatment of HIV infections

Antibody discovered that blocks almost all known HIV variants in neutralization assays - The discovery potentially opens up new perspectives for the prevention and treatment of HIV infections

New method for measuring luminescence lifetime offers breakthrough in scientific imaging - Ac­cel­er­at­ing the pace of dis­cov­ery in sci­ence and in­dustry

New method for measuring luminescence lifetime offers breakthrough in scientific imaging - Ac­cel­er­at­ing the pace of dis­cov­ery in sci­ence and in­dustry

Decreasing biodiversity may promote spread of viruses - New insight into the dynamics of infectious disease

Decreasing biodiversity may promote spread of viruses - New insight into the dynamics of infectious disease

Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies - Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors

Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies - Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors

3D-printed pills with desired drug release – a step upwards in medication - Funny looking pills are not a design gimmick, they can release medication in a desired time regime!

3D-printed pills with desired drug release – a step upwards in medication - Funny looking pills are not a design gimmick, they can release medication in a desired time regime!

Coronavirus SARS-CoV-2 spreads more indoors at low humidity - Indian-German research team recommends at least 40 percent humidity in public buildings

Coronavirus SARS-CoV-2 spreads more indoors at low humidity - Indian-German research team recommends at least 40 percent humidity in public buildings

Chemische Fabrik Dr. Weigert GmbH & Co. KG - Hamburg, Germany

Chemische Fabrik Dr. Weigert GmbH & Co. KG - Hamburg, Germany

KNAUER now officially a place of the future

KNAUER now officially a place of the future